Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06196203 · ClinicalTrials.gov registry record · Phase 2
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
A Phase 2 study of Higher-risk Myelodysplastic Syndromes, sponsored by Akeso.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 15
- Study locations
NCT06196203 is a Phase 2 study of Higher-risk Myelodysplastic Syndromes that is actively recruiting participants, run by Akeso. The registered enrollment target is 90 participants. The trial reports 15 study locations across 13 states.
The verdict
NCT06196203, a Phase 2 study of Higher-risk Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Akeso.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG AK117
Study Locations (15)
Maryland
- American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda) - Bethesda
- Maryland Oncology-Columbia - Columbia
Ohio
- Gabrail Cancer Center - Canton
- Ohio State University - Columbus
California
- UCLA Ronald Reagan Medical Center - Los Angeles
Colorado
- Rocky Mountain Cancer Centers - Aurora
Connecticut
- Yale Cancer Center - New Haven
Florida
- Mid Florida Hematology and Oncology Center - Orange City
Missouri
- Washington University School of Medicine in St. Louis - St Louis
New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06196203
The ClinicalTrials.gov registry entry for NCT06196203 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akeso, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Higher-risk Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06196203 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Maryland, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT06196203 about?
NCT06196203 is a clinical study titled "A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes". This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
What is the current status of trial NCT06196203?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-02-07. Estimated completion is 2026-06.
What conditions does trial NCT06196203 study?
This clinical trial studies the following conditions: Higher-risk Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06196203?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), AK117 (DRUG).
Who is sponsoring clinical trial NCT06196203?
This trial is sponsored by Akeso, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06196203 being conducted?
This trial has 15 study locations across California, Colorado, Connecticut, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Higher-risk Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.